N-丁環己胺 | 10108-56-2

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-丁環己胺
• 英文名称: N-butylcyclohexylamine
• 英文别名: N-butylcyclohexanamine；N-n-butylcyclohexylamine；butyl(cyclohexyl)amine；N-cyclohexylbutylamine
• CAS: 10108-56-2
• 化学式: C₁₀H₂₁N
• mdl: MFCD01735200
• 分子量: 155.283
• InChiKey: VXXLEXCQCSPKFI-UHFFFAOYSA-N

物化性质

• 熔点：
  208.3°C
• 沸点：
  209.13°C (estimate)
• 密度：
  0.8429 (estimate)
• 闪点：
  200 °F (93 °C) OC
• 溶解度：
  SLIGHTLY SOL IN WATER; VERY SOL IN ALCOHOL, ETHER
• 保留指数：
  1185

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

ADMET

毒理性

• 非人类毒性摘录

丁环己胺对兔眼刺激性评分为9。/在兔眼外部进行测试，根据24小时后观察到的伤害程度，按照1到10的等级进行数值评分，特别关注角膜的状况。最严重的伤害评为10分。

N-BUTYLCYCLOHEXYLAMINE RATED 9 ON RABBIT EYES. /TESTED EXTERNALLY ON EYES OF RABBITS, RATED NUMERICALLY ON SCALE OF 1 TO 10 ACCORDING TO DEGREE OF INJURY OBSERVED AFTER 24 HR, PAYING PARTICULAR ATTENTION TO CONDITION OF CORNEA. MOST SEVERE INJURIES HAVE BEEN RATED 10/.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 海关编码：
  2921300090
• 储存条件：
  库房应保持低温、干燥和通风，并将该区域与其他氧化剂及食品原料分开存放。

制备方法与用途

类别：易燃液体
毒性分级：高毒
急性毒性（口服-大鼠）：LD50 = 330 毫克/公斤
刺激数据：皮肤-兔 0.1 毫克/24 小时 中度
可燃性危险特性：遇热、明火易燃；热分解排出有毒氮氧化物烟雾
储运特性：应存放在低温干燥通风的库房中，与氧化剂和食品原料分开存放
灭火剂：水、干粉、二氧化碳、泡沫

反应信息

• 作为反应物：
  描述：

  N-丁環己胺 以53%的产率得到(丁基-lambda2-氮烷基)环己烷
  参考文献：
  名称：

  在KI催化量存在下苄基胺电化学氧化成相应的亚胺

  摘要：

  摘要 在非常温和的条件下，使用间接电化学方法成功地氧化了各种苄胺，并以良好的收率获得了相应的亚胺。我们的结果表明，对于该电解系统，碘离子作为电子载体起着重要的作用。

  DOI：

  10.1081/scc-200066648
• 作为产物：
  描述：

  (丁基-lambda2-氮烷基)环己烷 在 乙醇 、 铂 作用下， 生成 N-丁環己胺
  参考文献：
  名称：

  Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

  摘要：

  The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm Hg. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 mug/min; nifedipine, 59 mug/min; and placebo, 66 mug/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 g/min for perindopril, 122 mug/min for nifedipine, and 112 mug/min for placebo patients (P < 0.01). in patients with more than 3 years' follow-up, median AERs decreased by 45% in the first year and then stabilized in the perindopril group, but increased by 17.6% in the nifedipine group and 27.6% in the placebo group (P < 0.03) in the first year, then increased progressively. In these same patients, there was a significant decline in glomerular filtration rate in the nifedipine group (-7.8 +/- 1.8 mL/min/1.73 m(2)/y), but not in the other two groups (perindopril, -1.0 +/- 1.2 mL/min/1.73 m(2)/y; placebo, -1.3 +/- 1.1 mL/min/1.73 m(2)/y; P = 0.004). At the end or the study, cessation of treatment for 3 months was associated with a doubling of AERs in the perindopril-treated group, but no change in the other two groups (P < 0.001). In conclusion, long-term perindopril therapy is more effective than nifedipine or placebo in delaying the progression of diabetic nephropathy and reducing AER to the normoalbuminuric range (<20 mug/min) in normotensive patients with type I diabetes and microalbuminuria. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(05)80003-4

文献信息

• Efficient nickel-catalysed<i>N</i>-alkylation of amines with alcohols
  作者：Anastasiia Afanasenko、Saravanakumar Elangovan、Marc C. A. Stuart、Giuseppe Bonura、Francesco Frusteri、Katalin Barta

  DOI：10.1039/c8cy01200h

  日期：——

  selective N-alkylation of amines with alcohols, that is in situ generated from Ni(COD)2 and KOH under ligand-free conditions. This novel method is very efficient for the functionalization of aniline and derivatives with a wide range of aromatic and aliphatic alcohols as well as diols and exhibits excellent functional group tolerance including halides, benzodioxane and heteroaromatic groups. Several TEM measurements

  通过借用氢策略使胺与醇选择性地进行N烷基化反应是一种突出的可持续催化方法，该方法产生水作为唯一的副产物，非常适合可广泛衍生自可再生能源的醇反应伙伴的催化转化资源。集中研究致力于开发主要基于昂贵的贵金属的新型催化剂。但是，用于这种转化的均相或非均相非贵金属催化剂的可用性非常有限。本文中，我们提出了一种高活性且非常易于制备的镍基催化剂体系，用于将胺与醇选择性地进行N-烷基化，该反应是就地进行的。在无配体条件下由Ni（COD）2和KOH生成。这种新方法对于苯胺及其衍生物与各种芳香族和脂肪族醇以及二醇的官能化非常有效，并且具有出色的官能团耐受性，包括卤化物，苯并二恶烷和杂芳族基团。为了结合活性催化剂的性质和影响反应活性的因素，进行了几种TEM测量和元素分析的结合。
• Convenient Direct Reductive Amination of Carbonyl Compounds in a Completely Aqueous Media
  作者：Cristian Simion、Alina M. Simion、Takashi Arimura、Akira Miyazawa、Masashi Tashiro

  DOI：10.2174/157017810791514715

  日期：2010.7.1

  We report hereby a particularly efficient synthesis of secondary, and tertiary amines respectively, through a direct reductive amination process carried for the first time in a completely aqueous media.

  本文报告了一种特别高效的合成二级和三级胺的方法，首次在完全水相介质中通过直接还原胺化过程实现。
• Reduction of Imines and Enamines with Hydrogen Telluride. An Application to Reductive Alkylation of Amines with Carbonyl Compounds
  作者：Nobuaki Kambe、Tohru Inagaki、Noritaka Miyoshi、Akiya Ogawa、Noboru Sonoda

  DOI：10.1246/cl.1987.1275

  日期：1987.7.5

  Hydrogen telluride was found to reduce imines and enamines to the corresponding amines under mild conditions. As an application of this reduction,a new method for reductive alkylation of primary and secondary amines with ketones or aldehydes has been developed.

  发现碲化氢在温和条件下将亚胺和烯胺还原成相应的胺。作为这种还原的应用，开发了一种用酮或醛对伯胺和仲胺进行还原烷基化的新方法。
• Diethylsilane as a Powerful Reagent in Au Nanoparticle-Catalyzed Reductive Transformations
  作者：Anastasia Louka、Marios Kidonakis、Iakovos Saridakis、Elisavet-Maria Zantioti-Chatzouda、Manolis Stratakis

  DOI：10.1002/ejoc.202000483

  日期：2020.6.23

  Diethylsilane exhibits remarkable reactivity relative to typical hydrosilanes in the reduction of carbonyl compounds, imines, and amides catalyzed by Au nanoparticles.

  相对于典型的氢硅烷，二乙基硅烷在由Au纳米颗粒催化的羰基化合物，亚胺和酰胺的还原中表现出显着的反应性。
• New adenosine receptor ligands and uses thereof
  申请人：Domain Therapeutics

  公开号：EP2210891A1

  公开（公告）日：2010-07-28

  The present invention provides new compounds with high affinity for adenosine A2A receptors. It also provides antagonists of adenosine A2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A2A receptors signalling pathways could be beneficial such as Alzheimer's disease, Parkinson's disease, attention deficit and hyperactivity disorders (ADHD), Huntington's disease, neuroprotection, schizophrenia, anxiety and pain. The present invention further relates to pharmaceutical compositions containing such new compounds with high affinity for adenosine A2A receptors and their use for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A2A receptors could be beneficial.

  本发明提供了对腺苷A2A受体具有高亲和力的新化合物。它还提供了腺苷A2A受体的拮抗剂，以及它们作为药物用于治疗和/或预防部分或完全失活腺苷A2A受体信号通路可能有益的疾病和疾病，如阿尔茨海默病、帕金森病、注意力缺陷和多动症（ADHD）、亨廷顿病、神经保护、精神分裂症、焦虑和疼痛。本发明还涉及含有对腺苷A2A受体具有高亲和力的新化合物的药物组合物，以及它们用于治疗和/或预防部分或完全失活腺苷A2A受体可能有益的疾病和疾病。

表征谱图